Zobrazeno 1 - 10
of 588
pro vyhledávání: '"April W. Armstrong"'
Autor:
Kaviyon Sadrolashrafi, Audrey Hao, Rebecca K. Yamamoto, Lily Guo, Robin Kikuchi, Hannah C. Tolson, Sara N. Bilimoria, Danielle K. Yee, April W. Armstrong
Publikováno v:
BMC Health Services Research, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background Psoriasis is a chronic, inflammatory skin condition requiring long-term care. However, many psoriasis patients may not regularly receive care. Several factors affect access to care in the United States, including health insurance
Externí odkaz:
https://doaj.org/article/aed31ef13b8d4de19ca6832ea70bb2fd
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 11, Pp 3071-3081 (2024)
Abstract Introduction Despite advancements in the treatment of psoriasis (PsO), there are few head-to-head studies assessing comparative effectiveness of the newest therapies approved to treat PsO. Our objective was to assess the comparative clinical
Externí odkaz:
https://doaj.org/article/4674a01da9764f109764140e3aba0925
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 10, Pp 2709-2726 (2024)
Abstract Factors such as obesity, alcohol consumption, and tobacco use are associated with both increased psoriasis severity and inadequate response to systemic and biologic therapies. Obesity is linked to chronic inflammation, which can contribute t
Externí odkaz:
https://doaj.org/article/a4951cfff9df4cedae8ef0155d68cb57
Autor:
April W. Armstrong, Peter Foley, Yan Liu, Megan Miller, Rachel E. Teneralli, Anthony Bewley, Kenneth B. Gordon, Kim A. Papp, Chenglong Han
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2577-2589 (2024)
Abstract Introduction Treating plaque psoriasis (PsO) with guselkumab (GUS) promotes skin clearance and is associated with improvements in health-related quality of life (HRQoL), anxiety, and depression. It is unclear whether improvements in patient-
Externí odkaz:
https://doaj.org/article/2e1fbdbdc341498ebebba1f697824c23
Autor:
April W. Armstrong, H. Chih-Ho Hong, Brian M. Calimlim, Marric G. Buessing, Marjorie M. Crowell, Jonathan I. Silverberg
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2457-2465 (2024)
Abstract Introduction Efficacy of upadacitinib has been assessed in trials including Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422), and Heads Up (NCT03738397). Measure Up 1 and 2 assessed efficacy of upadacitinib 30 mg and upadacitinib 15 mg
Externí odkaz:
https://doaj.org/article/c50f79e2bc6f4b5e8459d5588f42735c
Autor:
April W. Armstrong, Matthias Augustin, Jennifer L. Beaumont, Tan P. Pham, Stacie Hudgens, Kenneth B. Gordon, Joe Zhuo, Brandon Becker, Yichen Zhong, Renata M. Kisa, Subhashis Banerjee, Kim A. Papp
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 8, Pp 2235-2248 (2024)
Abstract Introduction Deucravacitinib, a novel, oral, selective allosteric tyrosine kinase 2 inhibitor, demonstrated superiority versus placebo and apremilast in the POETYK PSO-1 and PSO-2 studies. We describe patient-reported outcomes with deucravac
Externí odkaz:
https://doaj.org/article/eb30f9d6f1ac4e2b804fb11e94392dce
Autor:
Neil J. Korman, Richard B. Warren, Jerry Bagel, April W. Armstrong, Melinda Gooderham, Bruce Strober, Diamant Thaçi, Akimichi Morita, Shinichi Imafuku, Peter Foley, Howard Sofen, Min Zheng, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Andrew Blauvelt
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
Aim: In the global phase 3 POETYK PSO-1 and PSO-2 trials, significantly greater proportions of deucravacitinib-treated patients met the coprimary endpoints (PASI 75, sPGA 0/1) at Week 16 versus placebo or apremilast-treated patients. This analysis ev
Externí odkaz:
https://doaj.org/article/565ff6e9db3f40f3996833c3bba76026
Autor:
Hannah Tolson, Robin Kikuchi, Rebecca K. Yamamoto, Kaviyon Sadrolashrafi, Lily Guo, Audrey Hao, Sara Bilimoria, Danielle Yee, April W. Armstrong
Publikováno v:
Skin Health and Disease, Vol 4, Iss 5, Pp n/a-n/a (2024)
Abstract Background Oral antibiotics are a mainstay of treatment for hidradenitis suppurativa (HS) primarily due to their anti‐inflammatory and anti‐microbial properties. Because antibiotics are frequently prescribed to treat HS, concerns exist r
Externí odkaz:
https://doaj.org/article/0dd562e5580247ff913a7e1caed0866b
Autor:
April W. Armstrong, Andrew F. Alexis, Andrew Blauvelt, Jonathan I. Silverberg, Claire Feeney, Mark Levenberg, Gary Chan, Fan Zhang, Luke Fostvedt
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 7, Pp 1849-1861 (2024)
Abstract Introduction Early prediction of abrocitinib efficacy in atopic dermatitis (AD) could help identify candidates for an early dose increase. A predictive model determined week 12 efficacy based on week 4 responses in patients receiving abrocit
Externí odkaz:
https://doaj.org/article/4fcba376017f4075bfd6d2381581d150
Autor:
April W. Armstrong, Sang Hee Park, Vardhaman Patel, Pierre Nicolas, Wei-Jhih Wang, Matthew J. Colombo, Viktor Chirikov
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 7, Pp 1891-1899 (2024)
Abstract Introduction Deucravacitinib demonstrated superior efficacy to apremilast in patients with moderate to severe plaque psoriasis in the POETYK PSO-1 and PSO-2 clinical trials. In the study reported here, we aimed to determine the overall 52-we
Externí odkaz:
https://doaj.org/article/1aec112419374b6eb1dbe535de388b5c